எல்பி மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs
02-Feb-2021
LB Pharmaceuticals Announces the Initiation of Patient Dosing in Open Label Phase 1b Imaging Study of LB-102
NEW YORK (BUSINESS WIRE) #LB102 LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1b clinical trial (Clinical Trials Identifier NCT04588129). This clinical study is designed to evaluate the dopamine receptor occupancy of LB-102 in healthy subjects using positron emission tomography (PET).
LB-102, a more lipophilic version of amisulpride, was designed to improve on amisulpride’s notoriously poor membrane (BBB) permeability while matching amisulpride’s binding affinity to the D ....

United States , Zachary Prensky , Lb Pharmaceuticals Inc , American Psychological Association , Lb Pharmaceuticals , Clinical Trials Identifier , ஒன்றுபட்டது மாநிலங்களில் , எல்பி மருந்துகள் இன்க் , அமெரிக்கன் உளவியல் சங்கம் , எல்பி மருந்துகள் ,